Loring Wolcott & Coolidge Fiduciary Advisors LLP Gh Research PLC Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $11.1 Billion
- Q3 2024
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Gh Research PLC stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 2,000 shares of GHRS stock, worth $16,660. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000
Previous 2,000
-0.0%
Holding current value
$16,660
Previous $23,000
43.48%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding GHRS
# of Institutions
34Shares Held
23.5MCall Options Held
63.1KPut Options Held
1.9K-
Bvf Inc San Francisco, CA10.4MShares$86.6 Million3.71% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.6MShares$55 Million1.16% of portfolio
-
Rtw Investments, LP New York, NY3.33MShares$27.7 Million0.65% of portfolio
-
Verition Fund Management LLC Greenwich, CT1.14MShares$9.5 Million0.08% of portfolio
-
Cormorant Asset Management, LP Boston, MA593KShares$4.94 Million0.53% of portfolio
About GH Research PLC
- Ticker GHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,020,800
- Market Cap $433M
- Description
- GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...